National Survey of Hospital Fungal Susceptibility Testing Practices

M. P. PAI, J. L. PRAUSE, S. L. PENDLAND

Author address: 

1Aristotle Univ, Thessaloniki, Greece, 2NCI, NIH, Bethesda, MD.

Abstract: 

Background: Antifungal susceptibility testing (AST) has historically been performed by a limited number of clinical labs. An assesssment of the extent of AST across the nation since the introduction of the NCCLS M27-A document has not been conducted. The present survey was performed to determine AST practices in teaching hospitals. Methods: A questionaire was mailed to microbiology lab directors at 386 teaching hospitals identified through the 2000 American Hospital Association Guide. The questionaire was remailed to non-responders 3 weeks after the initial mailing. The number of beds and total number of inpatient days for the year 2000 were determined for institutions through the American Hospital Directory. Results: The questionaire was returned by 115 (30%) institutions. Hospital bed size (number) distribution was 800 (11). Total and median (range) number of Candida isolates reported were 100,642 and 9 (1-145)/1000 inpatient days, respectively. AST was performed for 86 (75%) hospitals for a median 1% of Candida isolates. Isolate culture sites for MIC determination were blood (83.5%), urine (6%), oropharyngeal (1.5%). AST was conducted on-site by 22 hospitals and off-site for 64 hospitals (using 18 different labs). The NCCLS M27-A method was used by 68% of hospitals performing on-site AST, with the broth microdilution procedure used 73% of the time. The average time (
2001

abstract No: 

NULL

Full conference title: 

ICAAC 41st
    • ICAAC 41st